Barve, M., Bender, J., Pappen, B., Ishioka, G., Morse, M. A., Greco, F. A., … Nemunaitis, J. J. (2008). Induction of immune responses and clinical activity in a phase II trial of IDM-2101, a 10-epitope CTL vaccine, in metastatic NSCLC patients. Journal of Clinical Oncology, 26(15_suppl), 8057–8057. https://doi.org/10.1200/jco.2008.26.15_suppl.8057

Barve, M., J. Bender, B. Pappen, G. Ishioka, M. A. Morse, F. A. Greco, D. McCune, R. Steis, H. Khong, and J. J. Nemunaitis. “Induction of immune responses and clinical activity in a phase II trial of IDM-2101, a 10-epitope CTL vaccine, in metastatic NSCLC patients.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 8057–8057. https://doi.org/10.1200/jco.2008.26.15_suppl.8057.

Barve M, Bender J, Pappen B, Ishioka G, Morse MA, Greco FA, et al. Induction of immune responses and clinical activity in a phase II trial of IDM-2101, a 10-epitope CTL vaccine, in metastatic NSCLC patients. Journal of Clinical Oncology. 2008 May 20;26(15_suppl):8057–8057.

Barve, M., et al. “Induction of immune responses and clinical activity in a phase II trial of IDM-2101, a 10-epitope CTL vaccine, in metastatic NSCLC patients.” Journal of Clinical Oncology, vol. 26, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2008, pp. 8057–8057. Crossref, doi:10.1200/jco.2008.26.15_suppl.8057.

Barve M, Bender J, Pappen B, Ishioka G, Morse MA, Greco FA, McCune D, Steis R, Khong H, Nemunaitis JJ. Induction of immune responses and clinical activity in a phase II trial of IDM-2101, a 10-epitope CTL vaccine, in metastatic NSCLC patients. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008 May 20;26(15_suppl):8057–8057.